Honeylet Wortman‐Vayn

Statistics

Publications

Citations

H-Index

Active since

2013

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

Tennessee Oncology

University of California, San Francisco

Levine Cancer Institute

Bluebird Bio (United States)

Honeylet Wortman‐Vayn is an author at Bristol-Myers Squibb (Switzerland) specializing in hematologic malignancy therapy, medicine, and allogeneic car t-cell therapy.

Publications per year

2013–2021

Publications

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Jian Hou, Xin Du, Jie Jin et al. · Journal of Hematology & Oncology · 2013 · 51 citations · Full text

Medicine, Pharmacokinetics, Pharmacotherapy +14

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, Jesús G. Berdeja, Anna Truppel-Hartmann et al. · Blood · 2020 · 21 citations

Medicine, Hematology, Oncology +17

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

Saad Z. Usmani, Jesús G. Berdeja, Anna Truppel-Hartmann et al. · Journal of Clinical Oncology · 2021 · 19 citations

Medicine, Oncology, Cancer Immunology +11

1–3 of 3